Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1

Neurology

Volumn 74, Issue 18, 2010, Pages 1441-1448

  Logigian, E L ^a   Martens, W B ^a   Moxley, R T ^a,a   McDermott, M P ^a,b   Dilek, N ^a   Wiegner, A W ^c   Pearson, A T ^b   Barbieri, C A ^a   Annis, C L ^a   Thornton, C A ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEXILETINE; PLACEBO;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GRIP STRENGTH; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOTONIC DYSTROPHY; OUTCOME ASSESSMENT; PR INTERVAL; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SORE THROAT; TREMOR;

EID: 77951848201     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181dc1a3a     Document Type: Article

References (40)

1. Fu YH, Pizzuti A, Fenwick RG, et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 1992;255:1256-1258.
2. Harper PS. Myotonic Dystrophy, 3rd ed. London: WB Saunders; 2001.
3. Moxley RT III. Myotonic Dystrophy: Handbook of Clinical Neurology. New York: Elsevier Science; 1992: 209-259.
4. Leyburn P, Walton JN. The treatment of myotonia: a controlled clinical trial. Brain 1959;82:81-91.
5. Wolf A. Quinine: an effective form of treatment of myoto-nia. Arch Neurol Psychiatry 1936;36:382-384.
6. Geschwind N, Simpson JA. Procaine amide in the treatment of myotonia. Brain 1955;78:81-91.
7. Kwiecinski H, Ryniewicz B, Ostrzycki A. Treatment of Myotonia with antiarrhythmic drugs. Acta Neurol Scand 1992;86:371-375.
8. Mielke U, Haass A, Sen S, Schmidt W. Antimyotonic therapy with tocainide under ECG-control in the myo-tonic dystrophy of Curschmann-Steinert. J Neurol 1985; 232:271-274.
9. Munsat TL. Therapy of myotonia: a double-blind evaluation of diphenylhydantoin, procainamide, and placebo. Neurology 1967;17:359-367.
10. Rudel R, Dengler R, Ricker K, Haass A, Emser W. Improved therapy of myotonia with the lidocaine derivative tocainide. J Neurol 1980;222:275-278.
11. Sechi GP, Traccis S, Durelli L, Monaco F, Mutani R. Car-bamazepine versus diphenylhydantoin in the treatment of myotonia. Eur Neurol 1983;22:113-118.
12. Antonini G, Vichi R, Leardi MG, Pennisi E, Monza GC, Millefiorini M. Effect of clomipramine on myotonia: a placebo-controlled, double-blind, crossover trial. Neurology 1990;40:1473-1474.
13. Gascon GG, Staton RD, Patterson BD, et al. A pilot controlled study of the use of imipramine to reduce myotonia. Am J Phys Med Rehabil 1989;68:215-220.
14. Milner-Brown HS, Miller RG. Myotonic dystrophy: quantification of muscle weakness and myotonia and the effect of amitriptyline and exercise. Arch Phys Med Reha-bil 1990;71:983-987.
15. Grant R, Sutton DL, Behan PO, Ballantyne JP. Nifedi-pine in the treatment of myotonia in myotonic dystrophy. J Neurol Neurosurg Psychiatry 1987;50:199-206.
16. Lewis I. Trial of diazepam in myotonia: a controlled clinical trial. Neurology 1966;16:831-836.
17. Sugino M, Ohsawa N, Ito T, et al. A pilot study of dehy- droepiandrosterone sulfate in myotonic dystrophy. Neurology 1998;51:586-589.
18. Durelli L, Mutani R, Fassio F. The treatment of myotonia: evaluation of chronic oral taurine therapy. Neurology 1983;33:599-603.
19. Griggs RC, Moxley RT III, Riggs JE, Engel WK. Effects of acetazolamide on myotonia. Ann Neurol 1978;3:531-537.
20. Ceccarelli M, Rossi B, Siciliano G, Calevro L, Tarantino E. Clinical and electrophysiological reports in a case of early onset myotonia congenita (Thomsen's disease) successfully treated with mexiletine. Acta Paediatr 1992;81: 453-455.
21. Jackson CE, Barohn RJ, Ptacek LJ. Paramyotonia con-genita: abnormal short exercise test, and improvement after mexiletine therapy. Muscle Nerve 1994;17:763-768.
22. Pouget J, Serratrice G. [Myotonia with muscular weakness corrected by exercise: the therapeutic effect of mexiletine.] Rev Neurol 1983;139:665-672.
23. Ricker K, Haass A, Rudel R, Bohlen R, Mertens HG. Successful treatment of paramyotonia congenita (Eulenburg): muscle stiffness and weakness prevented by tocainide. J Neurol Neurosurg Psychiatry 1980;43:268-271.
24. Streib EW. Successful treatment with tocainide of recessive generalized congenital myotonia. Ann Neurol 1986;19: 501-504.
25. Rawson NS, Harding SR, Malcolm E, Lueck L. Hospital-izations for aplastic anemia and agranulocytosis in Saskatchewan: incidence and associations with antecedent prescription drug use. J Clin Epidemiol 1998;51:1343-1355.
26. Trip J, Drost G, van Engelen BGM, Faber CG. Drug treatment for myotonia. Cochrane Database of Systematic Reviews 2006.
27. Griggs RC, Wood DS. Criteria for establishing the validity of genetic recombination in myotonic dystrophy. Neurology 1989;39:420-421.
28. Logigian EL, Blood CL, Dilek N, et al. Quantitative analysis of the "warm-up" phenomenon in myotonic dystrophy type 1. Muscle Nerve 2005;32:35-42.
29. Moxley RT, Logigian EL, Martens WB, et al. Computerized hand grip myometry reliably measures myotonia and muscle strength in myotonic dystrophy (DM1). Muscle Nerve 2007;36:320-328.
30. Ravin A. Studies in dystrophia myotonia: III: experimental studies in myotonia. Arch Neurol Psychiatry 1940;43: 649-681.
31. Roden DM. Antiarrhythmic drugs. In: Brunton L, Parker J, Lazo K, eds. Goodman and Gillman's The Pharmacological Basis of Therapeutics. New York: McGraw Hill Publishing; 2005;899-932.
32. Shimizu W, Antzelevitch C. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade de pointes in LQT2 and LQT3 models of the long-QT syndrome. Circulation 1997;96:2038-2047.
33. Jurkat-Rott K, Lehmann-Horn F. Human muscle voltage-gated ion channels and hereditary disease. Curr Opin Pharmacol 2001;1:280-287.
34. Lehmann-Horn F, Jurkat-Rott K. Voltage-gated ion channels and hereditary disease. Physiol Rev 1999;79:1317-1372.
35. Cannon SC. Spectrum of sodium channel disturbances in the nondystrophic myotonias and periodic paralyses. Kidney Int 2000;57:772-779.
36. Mohammadi B, Jurkat-Rott K, Alekov A, Dengler R, Bufler J, Lehmann-Horn F. Preferred mexiletine block of human sodium channels with IVS4 mutations and its pH-dependence. Pharmacogenet Genomics 2005;15:235-244.
37. Takahashi MP, Cannon SC. Mexiletine block of disease-associated mutations in S6 segments of the human skeletal muscle Na(+) channel. J Physiol 2001;537:701-714.
38. Wang GK, Russell C, Wang SY. Mexiletine block of wild-type and inactivation-deficient human skeletal muscle hNav1.4 Na+ channels. J Physiol 2004;554:621-633.
39. Griggs RC, Davis RJ, Anderson DC, Dove JT. Cardiac conduction in myotonic dystrophy. Am J Med 1975;59: 37-42.
40. Campbell RW. Mexiletine. N Engl J Med 1987;316:29-34.